| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 09/26/2001 | EP1135131A1 Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |
| 09/26/2001 | EP1135128A2 Novel method of treatment |
| 09/26/2001 | EP1135127A1 New pharmaceutical composition and the process for its preparation |
| 09/26/2001 | EP1135126A2 Myt1 kinase inhibitors |
| 09/26/2001 | EP1135124A2 Antihypertriglyceridemic, antihyperglycemic, anti-angiogenic and wound healing substituded indolealkanoic acids |
| 09/26/2001 | EP1135123A1 Use of isatin derivatives as ion channel activating agents |
| 09/26/2001 | EP1135119A1 Glucose and lipid lowering compounds |
| 09/26/2001 | EP1135115A2 Use of sibutramine for the treatment of disorders of the central nervous system secondary to organic impairments |
| 09/26/2001 | EP1135107A1 Utilisation of capsules containing one or more antigenic substances for the prevention and/or treatment of autoimmune diseases |
| 09/26/2001 | EP0738727B1 1,4-benzoxazine-2-acetic acid compound, process for producing the same, and use thereof |
| 09/26/2001 | CN1314943A Method for producing plants with increased flavonoid and phenolic compound content |
| 09/26/2001 | CN1314912A Tartrate salt of a sabstituted dipentide as growth hormone secretagogue |
| 09/26/2001 | CN1314910A Adenosine derivatives |
| 09/26/2001 | CN1314818A Method for administering insulinotropic peptides |
| 09/26/2001 | CN1314181A Chinese patent medicine for treating hyperlipemia and its preparing method |
| 09/26/2001 | CN1314170A Medicine for treating diabetes and its preparation process |
| 09/26/2001 | CN1314163A Extracting deoxy enamine mycin derivatives by folium mori and medical use |
| 09/26/2001 | CN1314160A Oral pill for curing diabetes and its complication |
| 09/26/2001 | CN1314157A Traditional Chinese medicine for curing diabetes and kidney deficiency |
| 09/26/2001 | CN1314153A Mineral salt composition and its use |
| 09/26/2001 | CN1071790C Variants of bile salt-stimulated lipase, its preparation, use and nucleic acid for coding it |
| 09/26/2001 | CN1071760C N-terminally chemically modified protein composition and methods |
| 09/26/2001 | CN1071759C Biologically active peptides from functional domains of bactericidal/permeability-increasing protein and use thereof |
| 09/26/2001 | CN1071743C Sulfuryl or sulfufiny/benzoyl guanidine derivative |
| 09/25/2001 | US6294680 Process for the production of semi synthetic statins via novel intermediates |
| 09/25/2001 | US6294580 For therapy and prophylaxis of type ii or non-insulin dependent diabetes mellitus, hyperglycaemia, dyslipidemia, type ii diabetes, type i diabetes, hypertriglyceridemia, syndrome x, insulin resistance, heart failure |
| 09/25/2001 | US6294538 Antidiabetic agents and diabetic neuropathy, treatment with oxidoreductase enzymes |
| 09/25/2001 | US6294531 Calcilytic compounds |
| 09/25/2001 | US6294525 Reverse-turn mimetics and methods relating thereto |
| 09/25/2001 | US6294522 Compounds for treatment of cardiovascular disorders |
| 09/25/2001 | US6294197 Known to be effective in the treatment of congestive heart failure and reducing blood pressure. |
| 09/25/2001 | US6294196 Pharmaceutical composition containing diphosphonic acid or salt thereof |
| 09/25/2001 | US6294153 Aerosol pharmaceutical formulation for pulmonary and nasal delivery |
| 09/25/2001 | CA2214601C Mercapto and seleno derivatives as inhibitors of nitric oxide synthase |
| 09/22/2001 | CA2341344A1 Use of glycogen phosphorylase inhibitors |
| 09/20/2001 | WO2001068888A2 Production of chimeric capsid vectors |
| 09/20/2001 | WO2001068860A1 Antibodies to human cd154 |
| 09/20/2001 | WO2001068828A2 Compositions and methods for regulated protein expression in gut |
| 09/20/2001 | WO2001068698A2 Non-selective cation channel |
| 09/20/2001 | WO2001068697A2 Methods and compositions for immunoregulation |
| 09/20/2001 | WO2001068660A1 Glucopyranosyloxy benzylbenzene derivatives, medicinal compositions containing the same and intermediates for the preparation of the derivatives |
| 09/20/2001 | WO2001068653A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 09/20/2001 | WO2001068652A1 Condensed imidazoles as histamine h3 receptor ligands |
| 09/20/2001 | WO2001068651A1 Condensed imidazoles as histamine h3 receptor ligands |
| 09/20/2001 | WO2001068646A1 Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 09/20/2001 | WO2001068643A2 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
| 09/20/2001 | WO2001068637A2 Method for the preparation of tetrahydrobenzothiepines |
| 09/20/2001 | WO2001068634A1 4-fluoroalkyl-2h-benzopyrans with anti-estrogenic activity |
| 09/20/2001 | WO2001068619A1 5-amide substituted diarylamines as mex inhibitors |
| 09/20/2001 | WO2001068614A2 5-substituted arylpyrimidines |
| 09/20/2001 | WO2001068609A1 1,2,3,4-tetrahydroisoquinoline derivatives |
| 09/20/2001 | WO2001068603A2 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl iv, processes for their preparation, and their use |
| 09/20/2001 | WO2001068582A1 Novel fatty acid analogous |
| 09/20/2001 | WO2001068136A1 Drugs for complications of diabetes and neuropathy and utilization thereof |
| 09/20/2001 | WO2001068127A1 Use of growth hormone in low dose |
| 09/20/2001 | WO2001068106A1 Preventives and/or remedies for hyperphosphatemia |
| 09/20/2001 | WO2001068092A2 Glycogen phosphorylase inhibitor |
| 09/20/2001 | WO2001068075A2 Method for increasing intestinal absorption of fat soluble vitamins in post-menopausal women and lower animals |
| 09/20/2001 | WO2001068058A1 Multilayer pharmaceutical product for release in the colon |
| 09/20/2001 | WO2001068055A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 09/20/2001 | WO2001067896A2 Method of producing oily suspensions of water-soluble vitamins |
| 09/20/2001 | WO2001067895A1 Carbohydrate system and a method for providing nutriton to a diabetic |
| 09/20/2001 | WO2001067889A1 Diabetic nutritionals |
| 09/20/2001 | WO2001032029A3 Compositions comprising edible oils or fats and phytosterols and/or phytostanols substantially dissolved therein |
| 09/20/2001 | WO2001029070A8 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 09/20/2001 | WO2001027109A3 Tert.-butyl-(7-methyl-imidazo[1,2-a]pyridine-3-yl)-amine derivatives |
| 09/20/2001 | WO2001016603A3 Analysis and treatment of body weight and eating disorders |
| 09/20/2001 | WO2001016358A3 Method of screening for triacyglycerol hydrolase inhibitors |
| 09/20/2001 | WO2000071506A9 Naphthalene ureas as glucose uptake enhancers |
| 09/20/2001 | WO2000009537A3 Compounds having growth hormone releasing activity |
| 09/20/2001 | US20010023292 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4 -(2,3 -dihydroxypropoxy)pyridin-2-yl)oxy)-4-hydroxybenzamidine, for example |
| 09/20/2001 | US20010023291 Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants |
| 09/20/2001 | US20010023259 Nutrients, drugs |
| 09/20/2001 | US20010023257 Hypotensive agents; anticholesterol agents |
| 09/20/2001 | US20010023253 Novel compound |
| 09/20/2001 | US20010022979 Naturally extracted and synthetic hypoglycemic or hypolipidemic compositions |
| 09/20/2001 | DE10013296A1 New nucleic acid encoding the non-selective cation channel OTRPC4, useful for treating osmolality-associated disorders, e.g. diabetes comprises the modulation of activity |
| 09/20/2001 | DE10013259A1 New stable complexes of acesulfame with trace elements e.g. zinc or copper, useful as taste-masked form of trace elements for use in foods, feedstuffs, pharmaceuticals or cosmetics |
| 09/20/2001 | DE10013029A1 Multilayer formulation for controlled drug release in colon, comprising drug-containing core having inner and outer coatings of acrylic copolymers with quaternary ammonium and anionic groups respectively |
| 09/20/2001 | CA2403442A1 Use of nateglinide alone or in combination for the treatment or prevention of diabetic complications |
| 09/20/2001 | CA2403393A1 Methods and compositions for immunoregulation |
| 09/20/2001 | CA2403241A1 Pharmaceutical compositions of glycogen phosphorylase inhibitors |
| 09/20/2001 | CA2403233A1 Glycogen phosphorylase inhibitor |
| 09/20/2001 | CA2403205A1 Compositions and methods of regulated protein expression in gut endocrine k cells |
| 09/20/2001 | CA2403109A1 Hydrochloride salts of 5-[4-[2-(n-methyl-n-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
| 09/20/2001 | CA2403017A1 5-amide substituted diarylamines as mex inhibitors |
| 09/20/2001 | CA2402948A1 Use of growth hormone in low dose |
| 09/20/2001 | CA2402898A1 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines |
| 09/20/2001 | CA2402549A1 Substituted beta-carbolines |
| 09/20/2001 | CA2402427A1 Dihydroimidazo[2,1-b]thiazole and dihydro-5h-thiazolo[3,2-a]pyrimidines as antidepressant agents |
| 09/20/2001 | CA2402276A1 Carbohydrate system and a method for providing nutriton to a diabetic |
| 09/20/2001 | CA2400106A1 Antibodies to human cd154 |
| 09/20/2001 | CA2373411A1 5-substituted arylpyrimidines |
| 09/20/2001 | CA2373110A1 Production of chimeric capsid vectors |
| 09/19/2001 | EP1134223A2 Acesulfam metal complexes, their preparation and use |
| 09/19/2001 | EP1134215A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases |
| 09/19/2001 | EP1133997A2 Treatment of immune diseases with beta-interferon |
| 09/19/2001 | EP1133989A2 Polymer compositions for use in therapy |
| 09/19/2001 | EP1133517A1 INTRACELLULAR TARGETED DELIVERY OF COMPOUNDS BY 70 kD HEAT SHOCK PROTEIN |
| 09/19/2001 | EP1133494A1 8-azabicyclo 3.2.1]oct-2-ene and -octane derivatives |